Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$5.02 -1.6%	$4.75	$1.00 ▼ $7.00	$45.22M	0.67	139,027 shs	13,715 shs
KLRS Kalaris Therapeutics	$2.51 +2.0%	$2.56	$2.14 ▼ $24.15	$46.01M	0.49	47,049 shs	67,709 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	N/A
TAOX Synaptogenix	$7.65 +18.6%	$0.00	$1.84 ▼ $11.98	$22.49M	1.87	279,270 shs	337,606 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+1.39%	-2.49%	-1.16%	+20.00%	+277.78%
KLRS Kalaris Therapeutics	-4.28%	+8.37%	-4.28%	+245,999,900.00%	+245,999,900.00%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%
TAOX Synaptogenix	-6.93%	-29.82%	+644,999,900.00%	+644,999,900.00%	+644,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.2369 of 5 stars	3.3	5.0	0.0	0.0	0.6	1.7	0.0
KLRS Kalaris Therapeutics	1.3201 of 5 stars	2.0	0.0	0.0	0.0	1.6	3.3	0.6
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	139.04% Upside
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	19.52% Upside
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TAOX, ATHE, KLRS, and NBRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-277.76%	-150.79%	N/A

Latest TAOX, ATHE, KLRS, and NBRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
KLRS Kalaris Therapeutics	N/A	11.98	11.98
NBRV Nabriva Therapeutics	0.12	0.85	0.52
TAOX Synaptogenix	N/A	20.52	72.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
KLRS Kalaris Therapeutics	66.05%
NBRV Nabriva Therapeutics	0.27%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
KLRS Kalaris Therapeutics	74.99%
NBRV Nabriva Therapeutics	1.63%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable
TAOX Synaptogenix	4	3.49 million	1.35 million	N/A

TAOX, ATHE, KLRS, and NBRV Headlines

Recent News About These Companies

Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

August 19 at 2:25 AM | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TAOX, ATHE, KLRS, and NBRV Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$5.02 -0.08 (-1.57%)

Closing price 03:59 PM Eastern

Extended Trading

$5.04 +0.02 (+0.30%)

As of 04:10 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Kalaris Therapeutics NASDAQ:KLRS

$2.51 +0.05 (+2.03%)

As of 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Synaptogenix NASDAQ:TAOX

$7.65 +1.20 (+18.60%)

As of 04:00 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time